Antisoma announces the presentation today at ASCO of initial findings from a phase II trial of AS1404 (DMXAA) in ovarian cancer. The study randomised patients with recurrent ovarian cancer to receive AS1404 plus chemotherapy or chemotherapy alone. With initial data available from 62 patients, those receiving AS1404 had a tumour response rate of 61.3%, compared with 54.8% for those receiving chemotherapy alone.
